---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-100436"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:31:13.879860+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M

## Summary
- Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.
- Added conversion feature at $0.06/share, initially convertible into 37.6M shares of common stock.
- True-up provision requires additional note if net proceeds from conversion sales fall short of principal.
- Company paid $15,000 documentation fee; beneficial ownership cap set at 4.99% (can be raised to 9.99%).
- Management says restructuring strengthens balance sheet and positions for sustained profitability.

## SEC filing metadata
- accession: 0001193125-26-100436
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000119312526100436/0001193125-26-100436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000119312526100436/cvsi-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-100436
- JSON: https://secwatch.observer/filing/0001193125-26-100436.json
- Plain text: https://secwatch.observer/filing/0001193125-26-100436.txt

## Source-grounded claims
- claim_id: b09eef451f14dc45be9340ad4a0303fed24a748f
  claim: CV Sciences, Inc. amended convertible notes of aggregate outstanding principal amount of $2,256,000 with institutional investor.
  evidence_excerpt: amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000119312526100436/0001193125-26-100436-index.htm
- claim_id: 951e727a798842d4396d74349b2cf89cef9818ae
  claim: CV Sciences, Inc. amended Agreement with an institutional investor ("Investor") valued at aggregate outstanding principal amount of $2,256,000 (effective 2026-03-04).
  evidence_excerpt: On March 4, 2026, the Company and the Investor entered into an agreement (the “Agreement”) to, among other things, amend and restate the Amended Original Note and the Second Note
  evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000119312526100436/0001193125-26-100436-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.